NX Development Corp et al., 2026-01-29: US label for aminolevulinic acid (Gleolan): its approved use in glioma is fluorescence visualisation during surgery, not photodynamic therapy – the approved brain-tumour photosensitizer in the US does not treat, it illuminates.
Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery.
Section 1 (Indications and Usage)
NX Development Corp et al., 2026-01-29: US label for aminolevulinic acid (Gleolan): its approved use in glioma is fluorescence visualisation during surgery, not photodynamic therapy – the approved brain-tumour photosensitizer in the US does not treat, it illuminates. C8 label record – glioblastoma/brain. Country: USA. Dose on the label: 20 mg/kg orally 3 hours before anaesthesia. Not methylene blue. Establishes that the FDA-approved agent in brain tumours is a surgical visualisation adjunct. Study type: regulatory record.
